GUERNSEY STATUTORY INSTRUMENT

2021 No. 172

The Medicines (Coronavirus and Influenza) (Bailiwick of Guernsey) (Amendment No. 4) Regulations, 2021

Made	*30th November, 2021*
Coming into operation	*1st January, 2022*
Laid before the States	*, 2021*

THE COMMITTEE FOR HEALTH & SOCIAL CARE, in exercise of the powers conferred on it by sections 7(3) and (3A), 15, 34, 39, 75 and 132 of the Medicines (Human and Veterinary) (Bailiwick of Guernsey) Law, 2008[a], section 15(3) of the Prescription Only Medicines (Human) (Bailiwick of Guernsey) Ordinance, 2009[b] (following consultation with the Policy & Resources Committee of the States of Guernsey, the Policy and Finance Committee of the States of Alderney and the Medical & Emergency Services Committee of the Chief Pleas) and all other powers enabling them in that behalf, hereby makes the following Regulations:-

---

a Order in Council No. V of 2009; amended by Ordinance No. XXIV of 2009; No. XLI of 2013; No. IX of 2016; the Medicines (Human and Veterinary) (Bailiwick of Guernsey) (Amendment) Ordinance, 2021; and G.S.I. No. 39 of 2019.

b Ordinance No. XXV of 2009; amended by No. XXV of 2010; No. IX of 2016; No. XXXIV of 2020.

Amendment of the 2020 Regulations.

1. The Medicines (Coronavirus and Influenza) (Bailiwick of Guernsey) Regulations, 2020[c] ("**the principal Regulations**") are amended as set out in regulation 2.

2. For regulation 1 of the principal Regulations, substitute the following regulation –

"**Designation of vaccines**.

1. "(1) Each medicinal product listed in the following table is designated to be used for vaccination or immunisation against the coronavirus-

1.	The COVID-19 Vaccine AstraZeneca, solution for injection in multidose container COVID-19 Vaccine (ChAdOx1-S [recombinant]), also known as the COVID-19 Vaccine AstraZeneca.

(2) The designation of a medicinal product under paragraph (1) is subject to any conditions specified by the UK licensing authority for the authorisation of the medicinal product on a temporary basis under regulation 174 of the Human Medicines Regulations 2012, which may include conditions specified under regulation 174A of those Regulations.

(3) In paragraph (2), "**the UK licensing authority**" means the licensing authority within the meaning given by regulation 6(2) of the Human Medicines Regulations 2012.".

---

[c] G.S.I. No. 125 of 2020; as amended by G.S.I. Nos. 3, 11 and 49 of 2021.

Citation.

3. These Regulations may be cited as the Medicines (Coronavirus and Influenza) (Amendment No. 4) (Bailiwick of Guernsey) Regulations, 2021.

Commencement

4. These Regulations shall come into force on the 1st January, 2022.

Dated this 30th day of November, 2021



Deputy A.H. Brouard

President of the Committee for Health & Social Care

For and on behalf of the Committee

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations amend the Medicines (Coronavirus and Influenza) (Bailiwick of Guernsey) Regulations, 2020 ("**the principal Regulations**").

Regulation 2 substitutes regulation 1 of the principal Regulations to provide that only the COVID-19 Vaccine AstraZeneca remains designated to be used for vaccination or immunisation against the coronavirus. The UK licensing authority has revoked the temporary authorisation previously given for the Pfizer-BioNTech COVID-19 Vaccine under regulation 174 of the Human Medicines Regulations 2012, so the Committee can no longer designate that vaccine.

These Regulations will come into force on the 1st January, 2022.